There is a high rate of failure in Alzheimer's disease (AD) drug development with 99% of
trials showing no drug-placebo difference. This low rate of success delays new treatments …

Introduction Alzheimer's disease and related dementias (ADRD) disproportionately impact
racial and ethnic minority and socioeconomically disadvantaged adults. Yet, these …

Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging
population and society as a whole. With the numbers of people with ADRDs predicted to rise …

Introduction Although dementia prevalence differs by race, it remains unclear whether
cognition and neuropsychiatric symptom severity differ between Black and White individuals …

It is well known that vascular factors and specific social determinants of health contribute to
dementia risk and that the prevalence of these risk factors differs according to race and sex …

Objective Numerous investigators have theorized that postoperative changes in Alzheimer's
disease neuropathology may underlie postoperative neurocognitive disorders. Thus, we …

Abstract The Washington University School of Medicine Knight Alzheimer Disease Research
Center's “African American Participation in Alzheimer Disease Research: Effective …

Introduction This study aimed to identify the relationship of sociodemographic variables with
older adults participation in an online registry for recruitment and longitudinal assessment in …

Introduction An analysis of the ethnocultural and socioeconomic composition of Alzheimer's
Disease Neuroimaging Initiative (ADNI) participants is needed to assess the generalizability …

Introduction To address the need for remote assessments of cognitive decline and dementia,
we developed and administered electronic versions of the Clinical Dementia Rating (CDR®) …